← Human Trials & Peer-Reviewed Studies
A Mushroom Based Prebiotic Supplement Pilot Study Among Patients with Crohn's Disease.
Plain-language guide to PMID 40313234 (2025): double-blind randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 40313234
- Journal
- Journal of dietary supplements
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Leibovitzh H et al. (7 authors)
- DOI
- 10.1080/19390211.2025.2498127
What This Study Did, in Plain Language
What Was Tested
Researchers studied Copper (Supplement) in this randomized controlled trial publication.
A multivariable linear mixed effects model was used to assess alteration in fecal microbiome composition and function pre- and post-'Mycodigest' intervention.
Why It Was Studied
Data on a mushroom based prebiotic supplementation in patients with Crohn's disease (CD) in western population is scarce.
Who Took Part
The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.
Patients with mild to moderate CD were recruited to a single center, randomized, double-blind, placebo-controlled pilot induction trial.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and pilot study.
Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.
Some participants received a placebo instead of Copper (Supplement), giving a reference point.
It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.
Fecal samples were assessed by DNA shotgun metagenomic sequencing.
What Was Measured
PubMed files the paper under topics including Prebiotics, Crohn Disease, Pilot Projects, Feces, Dietary Supplements, Agaricales and Gastrointestinal Microbiome.
The authors tagged it with the keywords C-reactive protein, Crohn’s disease, fecal calprotectin and mushroom.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).
The publication is from 2025 (Journal of dietary supplements), a journal based in England.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.